Terms ending in 2033
Every in-force patent on Atyr Pharma, Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,497,466 | Compositions and Methods Comprising Histidyl-Trna Synthetase Splice Variants Having Non-Canonical Biological Activities In force · High confidence | Pangu Biopharma Limited | In force | High confidence | |
| US 9,688,978 | Aspartyl-Trna Synthetase-Fc Conjugates In force · High confidence | Atyr Pharma, Inc. | In force | High confidence | |
| US 9,822,353 | Pegylated Aspartyl-Trna Synthetase Polypeptides In force · High confidence | Atyr Pharma, Inc. | In force | High confidence | |
| US 9,816,084 | Aspartyl-Trna Synthetases In force · High confidence | Atyr Pharma, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Atyr Pharma, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.